Perhaps the biggest news in the immunization world over the past 2 years was the 2009
(H1N1) novel influenza A virus outbreak. The virus was initially identified to be
the cause of influenza-like illness in two children in the United States during March
and April 2009 and the cause of respiratory illness outbreaks in Mexico [
1
,
2
]. The virus spread rapidly and within weeks cases were identified across the United
States and in several countries around the world. On June 11, 2009 the Director General
of the World Health Organization (WHO) Dr Margaret Chan declared a global pandemic.
As of August 10, 2010, this has been updated to postpandemic status. This review focuses
on discussing the 2009 pandemic briefly along with the global response in terms of
vaccine development, recommendations for vaccination for the 2010–2011 influenza season,
followed by other recent updates in adolescent and pediatric vaccines.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in PediatricsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Swine influenza A (H1N1) infection in two children—Southern California, March-April 2009.MMWR Morb Mortal Wkly Rep. 2009; 58: 400-402
- Outbreak of swine-origin influenza A (H1N1) virus infection—Mexico, March-April 2009.MMWR Morb Mortal Wkly Rep. 2009; 58: 467-470
- The 2009 H1N1 influenza outbreak in its historical context.J Clin Virol. 2009; 45: 174-178
- Historical perspective-emergence of influenza A (H1N1) viruses.N Engl J Med. 2009; 361: 279-285
- Emergence of a novel swine-origin influenza A (H1N1) virus in humans.N Engl J Med. 2010; 360: 2605-2615
- 2009 H1N1 influenza: a twenty-first century pandemic with roots in the early twentieth century.Am J Med Sci. 2010; 340: 202-208
- Characterization of the 1918 influenza virus polymerase genes.Nature. 2005; 437: 889-893
- Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.Science. 2009; 325: 197-201
- The A/2009 H1N1 influenza virus pandemic.(update September 2009) Available at: (Accessed November 8, 2010)
- Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic.Bull Hist Med. 2002; 76: 105-115
- Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.N Engl J Med. 2009; 361: 2507-2517
- Novel influenza A (H1N1): clinical presentation, diagnosis and management.Pediatr Emerg Care. 2009; 25: 791-796
- Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.N Engl J Med. 2009; 361: 1935-1944
- Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States.(Available at)http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm(Accessed November 22, 2010)Date: April 2009-April 10, 2010
- (California Pandemic (H1N1) working group). Children hospitalized with 2009 novel influenza A(H1N1) in California.Arch Pediatr Adolesc Med. 2010; 164: 1023-1031
- Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection.Pediatr Infect Dis J. 2010; 29: 591-594
Custodio H, Carmen M, Bailey C, et al. Hospitalized children infected with the novel H1N1 (nH1N1) influenza: comparison of the ICU to non-ICU patients. Poster presentation, Infectious Diseases Society of America Annual Meeting. Vancouver British Columbia (Canada); October 21–24, 2010.
- Epidemiologic and clinical features among patients hospitalized in Wisconsin with 2009 H1N1 influenza A virus infections, April to August 2009.WMJ. 2010; 109: 201-208
- Pandemic A (H1N1) 2009 influenza; a review of the southern hemisphere experience.Epidemiol Infect. 2011; 139: 27-40
- Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the northern hemisphere.Eur J Clin Microbiol Infect Dis. 2010; 29: 1327-1347
- Cross reactive antibody responses to the 2009 pandemic H1N1 influenza virus.N Engl J Med. 2009; 361: 1945-1952
- Influenza vaccination in pregnancy: current evidence and selected national policies.Lancet Infect Dis. 2008; 8: 44-52
- Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray.Nat Biotechnol. 2009; 27: 797-799
- Correlates of protection induced by vaccination.Clin Vaccine Immunol. 2010; 17: 1055-1065
- Influenza vaccine-outmaneuvering antigenic shift and drift.N Engl J Med. 2004; 350: 218-220
- Influenza vaccine manufacture: keeping up with the change.J Infect Dis. 2009; 200: 835-837
- Response to a monovalent 2009 influenza A (H1N1) vaccine.N Engl J Med. 2009; 361: 2405-2413
- Immunogenicity of a monovalent 2009 influenza A(H1N1) in infants and children: a randomized trial.JAMA. 2010; 303: 37-46
- Immune response after a single vaccination against 2009 influenza A H1N1 in the USA: a preliminary report of two randomized controlled phase 2 trials.Lancet. 2010; 375: 41-48
- Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multi-center, double-blind, randomized, placebo-controlled trial.Lancet. 2010; 375: 56-66
- A single dose of unadjuvanted novel 2009H1N1 vaccine is immunogenic and well tolerated in young and elderly adults.J Infect Dis. 2010; 202: 1327-1337
- Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case control study in Mexico City.BMJ. 2009; 339: b3928
- Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong.Clin Infect Dis. 2010; 51: 1370-1379
- Pandemic and seasonal H1N1 influenza haemagglutinin-specific T cell responses elicited by seasonal influenza vaccination.Vaccine. 2010; 28: 8258-8267
- Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A (H1N1)2009 virus in an age-dependant manner.J Infect Dis. 2010; 202: 1634-1638
- Effectiveness of 2008–2009 trivalent influenza against 2009 pandemic influenza A (H1N1)—United States, May-June 2009.MMWR Morb Mortal Wkly Rep. 2009; 58: 1241-1245
- Adverse reaction of influenza A (H1N1) 2009 virus vaccination in pregnant women and its effect on newborns.Vaccine. 2010; 28: 7455-7456
- Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection-United States, April-August 2009.MMWR Morb Mortal Wkly Rep. 2009; 58: 941-947
- Helping mothers prevent influenza illness in their infants.Pediatrics. 2010; 126: 1008-1011
- Maternal influenza vaccination and effect on influenza virus infection in young infants.Arch Pediatr Adolesc Med. 2011; 165: 104-111https://doi.org/10.1001/archpediatrics.2010.192
- Mandatory vaccination of health care workers.N Engl J Med. 2009; 361: 2015-2017
- Policy statement—recommendation for mandatory influenza immunization of all health care personnel.Pediatrics. 2010; 126: 809-815
- Revised SHEA position paper: influenza vaccination of healthcare personnel.Infect Control Hosp Epidemiol. 2010; 31: 987-995
- Safety and immunogenicity following administration of a live attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.PLoS One. 2010; 5: e13755
- Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.Vaccine. 2010; 28: 7248-7255
- Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine-United States 2009-2010.MMWR Morb Mortal Wkly Rep. 2010; 59: 657-661
- Swine flu outbreak. China first to vaccinate against novel H1N1 virus.Science. 2009; 325: 1482-1483
- FDA 2009 H1N1 vaccine questions and answers.(Available at:) (Accessed November 25, 2010)
- The 2009 A (H1N1) influenza virus pandemic: a review.Vaccine. 2010; 28: 4895-4905
- Public views of the UK media and government reaction to the 2009 swine flu pandemic.BMC Public Health. 2010; 10: 697
- Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009–2010: results of a national vaccination campaign.Vaccine. 2010; 28: 8157-8161
- Pandemic (H1N1) 2009 influenza vaccine uptake in pregnant women entering the 2010 influenza season in Western Australia.Med J Aust. 2010; 193: 405-407
- Knowledge, attitudes and anxiety toward influenza A/H1N1 vaccination of healthcare workers in Turkey.BMC Infect Dis. 2010; 10: 281
- Perceived seriousness of seasonal and A(H1N1) influenzas, attitude toward vaccination and vaccine uptake among US adults: does the source of information matter?.Prev Med. 2010; 51: 185-187
- Practice and child characteristics associated with influenza vaccine uptake in young children.Pediatrics. 2010; 126: 665-673
- Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections.Clin Infect Dis. 2010; 51: 1033-1041
- Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States.N Engl J Med. 2009; 361: 2619-2627
- Comparative epidemiology of pandemic and seasonal influenza A in households.N Engl J Med. 2010; 362: 2175-2184
- Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009: an observational study.Epidemiol Infect. 2010; 138: 183-191
- Household transmission of 2009 influenza A (H1N1) virus after a school based outbreak In New York City, April-May 2009.J Infect Dis. 2010; 201: 984-992
- Closure of schools during an influenza pandemic.Lancet Infect Dis. 2009; 9: 473-481
- Update: influenza activity—United States 2009-10 season.MMWR Morb Mortal Wkly Rep. 2010; 59: 901-908
- Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.MMWR Recomm Rep. 2010; 59: 1-62
- Policy statement—recommendations for prevention and control of influenza in children, 2010-2011.Pediatrics. 2010; 126: 816-826
- Safety and immunogenicity of trivalent and inactivated influenza vaccine in infants: a randomized, double-blind, placebo-controlled study.Pediatr Infect Dis J. 2010; 29: 105-110
- Influenza activity—United States and worldwide, June 13-September 25, 2010.MMWR Morb Mortal Wkly Rep. 2010; 59: 1270-1273
- National, state and local area vaccination coverage among adolescents aged 13–17 years—United States, 2009.MMWR Morb Mortal Wkly Rep. 2010; 59: 1018-1023
- Whooping cough outbreak hits several US states.BMJ. 2010; 341: c4627
- The role of adults in household outbreaks of pertussis.Int J Infect Dis. 2010; 14: e111-e114
- Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy.Vaccine. 2010; 28: 5147-5152
- Use of mass Tdap vaccination to control an outbreak of pertussis in a high school—Cook County, Illinois, September 2006-January 2007.MMWR Morb Mortal Wkly Rep. 2008; 57: 796-799
- California Department of Health.(Available at:) (Accessed April 13, 2011)
- Infant pertussis: who was the source?.Pediatr Infect Dis J. 2004; 23: 985-989
- The case for maternal vaccination against pertussis.Lancet Infect Dis. 2007; 7: 614-624
- Prevention of pertussis, tetanus and diphtheria among pregnant and post partum women and their infants: recommendations of the Advisory Committee on Immunization Practices.MMWR Recomm Rep. 2008; 57: 1-51
- ACIP Presentation slides: October 2010 meeting.(Available at:) (Accessed November 25, 2010)
FDA Approval Letter-Menactra. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm131181.htm. Accessed November 25, 2010.
FDA Approval Letter-Menveo. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201343.htm. Accessed November 25, 2010.
- Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age.Vaccine. 2010; 28: 7865-7872
- Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine.MMWR Morb Mortal Wkly Rep. 2007; 56: 794-795
- ACIP Presentation Slides October 2010.(Available at:) (Accessed November 25, 2010)
- Revised Recommendations from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.MMWR Morb Mortal Wkly Rep. 2010; 58: 1042-1043
- Henoch-Schonlein purpura and polysaccharide meningococcal vaccine.Pediatrics. 2010; 126: e325-e329
- Review of meningococcal group B vaccines.Clin Infect Dis. 2010; 50: S54-S65
- Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.Clin Infect Dis. 2010; 51: 1127-1137
- Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.Pediatr Infect Dis J. 2010; 29: e71-e79
FDA Approval Letter-Cervarix. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186959.htm. Accessed November 27, 2010.
- Human papillomavirus and HPV vaccines: a review.Bull World Health Organ. 2007; 85: 719-726
- FDA licensure of bivalent human papillomavirus (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices.MMWR Morb Mortal Wkly Rep. 2010; 59: 626-629
- FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices.MMWR Morb Mortal Wkly Rep. 2010; 59: 630-632
- Economic evaluation of human papillomavirus vaccination in developed countries.Public Health Genomics. 2009; 12: 343-351
- Predictors of HPV vaccine acceptability: a theory-informed systematic review.Prev Med. 2007; 45: 107-114
- Parental decision making about HPV vaccine.Cancer Epidemiol Biomarkers Prev. 2010; 19: 2187-2198
- Reasons for non vaccination against HPV and future vaccination intentions in 19-26-year-old women.BMC Womens Health. 2010; 10: 27
- Acceptability of human papillomavirus vaccine for males: a review of the literature.J Adolesc Health. 2010; 46: 113-123
- Adolescent immunization: the next big thing?.Arch Dis Child. 2010; (Accessed online November 28, 2010)https://doi.org/10.1136/adc.2010.192070
- Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure.Pediatrics. 2010; 126: 425-433
- Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.N Engl J Med. 2003; 348: 1737-1746
- Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections.JAMA. 2004; 291: 2197-2203
- Changing epidemiology of invasive pneumococcal disease among older adult in the era of pediatric pneumococcal conjugate vaccine.JAMA. 2005; 294: 2043-2051
- Effect of introduction of the pneumococcal vaccine on drug-resistant Streptococcus pneumoniae.N Engl J Med. 2006; 354: 1455-1463
- Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.JAMA. 2006; 295: 1668-1674
- Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.J Infect Dis. 2010; 201: 32-41
- Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004.J Infect Dis. 2007; 196: 1346-1354
FDA Approval Letter- Prevnar 13. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201741.htm. Accessed November 28, 2010.
- Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010.MMWR Morb Mortal Wkly Rep. 2010; 59: 258-261
- Recommendations for the prevention of invasive Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).Pediatrics. 2010; 126: 186-190
- Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).MMWR Morb Mortal Wkly Rep. 2010; 59: 1102-1106
- Rotavirus Approval. 2008 Biologicals License Applications Approval.(Available at:) (Accessed November 29, 2010)
- Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.Pediatrics. 2010; 125: e208-e213
- Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.Pediatrics. 2010; 125: e199-e207
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomized double-blind placebo controlled trial.Lancet. 2010; 376: 615-623
- Rotarix in developing countries: paving the way for inclusion in national childhood immunization programs in Africa.J Infect Dis. 2010; 202: S80-S86
- Update on rotavirus trends and the importance of surveillance.Pediatr Infect Dis J. 2010; 29: 1130-1132
- FDA: benefits of rotavirus vaccination outweigh potential contamination risk.JAMA. 2010; 304: 30-31
- Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine.MMWR Morb Mortal Wkly Rep. 2010; 59: 687-688
- Vaccine preventable diseases: statement regarding Rotarix and Rotateq rotavirus vaccines and intussusception.(Available at:) (Accessed December 8, 2010)
- Immunogenicity and safety of an investigational combined Haemophilus influenzae type B—Neisseria meningitis serogroups C and Y-tetanus toxoid conjugate vaccine.Pediatr Infect Dis J. 2010; (Available at:) (Accessed November 27, 2010)
- Combined Haemophilus type b and Neisseria meningitides serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12–18 months of age.Hum Vaccin. 2010; 6: 640-651
- Invasive Haemophilus influenza type B disease in five children—Minnesota, 2008.MMWR Morb Mortal Wkly Rep. 2009; 58: 58-60
- Immunogenicity and safety of GSK Biologicals’ Infanrix Haxa in infants.(Available at:) (Accessed November 28, 2010)
- Hepatitis A in internationally adopted children: screening for acute and previous infections.Pediatrics. 2010; 126: e1039-e1044
- Medical evaluation of internationally adopted children for infectious diseases.in: Pickering L.K. Baker C.J. Kimberlin D.W. Red Book 2009: Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village (IL)2009: 177-184
- Infected countries.(Available at:) (Accessed November 28, 2010)
The GAVI Alliance. Available at: http://www.gavialliance.org/resources/GAVI_Alliance_Nov_2010.pdf. Accessed November 28, 2010.
- Progress towards control of rubella and prevention of congenital rubella syndrome—worldwide, 2009.MMWR Morb Mortal Wkly Rep. 2010; 59: 1307-1310
Article Info
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
